Cervicitis treatment
Reading File
Finding Sources
Searching PubMed
cervicitis treatment guidelines
Searching the Web
cervicitis treatment CDC guidelines 2025
Reading File
Reading File
Reading File
Reading Web Page
cervicitis treatment regimen
Reading File
I now have comprehensive information from Harrison's 22E (2025), Goldman-Cecil, the Washington Manual, and the CDC STI Treatment Guidelines. Here is the full answer:
Cervicitis Treatment
Overview
Cervicitis (most commonly mucopurulent/endocervicitis) is inflammation of the endocervical columnar epithelium, most often caused by Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, or HSV. Importantly, no organism is identified in nearly half of cases even with modern NAATs. Because it can progress to pelvic inflammatory disease (PID) and obstetric complications, prompt treatment is essential.
Step 1 - Diagnostic Testing Before/At Treatment
Test for all of the following using NAAT (vaginal or endocervical swab):
- N. gonorrhoeae and C. trachomatis (NAAT is the standard)
- T. vaginalis
- Bacterial vaginosis (BV)
- Consider HSV, syphilis, and HIV testing
Step 2 - Empiric vs. Deferred Treatment
Presumptive/Empiric Treatment - Indicated When:
- Patient is aged <25 years (high-risk)
- New sex partner, partner with concurrent partners, or partner with a known STI
- Follow-up cannot be ensured
- NAAT testing is not available
Defer Until Results Available When:
- Patient is at lower risk for STIs and reliable follow-up is possible
Recommended Regimens (CDC STI Treatment Guidelines / Harrison's 22E)
Chlamydia-directed empiric therapy (first-line)
| Drug | Dose |
|---|---|
| Doxycycline (preferred) | 100 mg orally twice daily x 7 days |
| Azithromycin (alternative) | 1 g orally single dose |
Add Gonorrhea Coverage If:
- High gonorrhea prevalence in the community, or patient is at risk
- Cannot rule out gonorrhea
| Drug | Dose |
|---|---|
| Ceftriaxone | 500 mg IM single dose |
Combine with doxycycline 100 mg PO twice daily x 7 days if C. trachomatis has not been ruled out.
If Gonorrhea is Positive (Confirmed):
- Ceftriaxone 500 mg IM single dose (primary)
- If ceftriaxone unavailable: Cefixime 800 mg PO x1 (not preferred; use only if ceftriaxone is unavailable)
- Add doxycycline 100 mg twice daily x 7 days if chlamydia co-infection not excluded
If Chlamydia is Positive (Confirmed):
- Doxycycline 100 mg PO twice daily x 7 days (preferred over azithromycin due to higher cure rates)
If Mycoplasma genitalium is Suspected or Identified:
- Without macrolide resistance testing: Doxycycline 100 mg PO twice daily x 7 days, followed by moxifloxacin 400 mg PO daily x 7 days
- With resistance testing available:
- Macrolide-sensitive: Doxycycline x 7 days, then azithromycin 1 g PO x1 then 500 mg PO x 3 days
- Macrolide-resistant: Doxycycline x 7 days, then moxifloxacin 400 mg PO x 7 days
- Note: M. genitalium frequently persists after doxycycline alone; azithromycin or moxifloxacin are required
If T. vaginalis or BV is Detected:
Treat concurrently per standard regimens:
- Trichomoniasis: Metronidazole 500 mg PO twice daily x 7 days (women)
- BV: Metronidazole 500 mg PO twice daily x 7 days
Special Populations
Pregnancy
- Follow gonorrhea-in-pregnancy and chlamydia-in-pregnancy regimens
- Avoid doxycycline - use azithromycin 1 g PO single dose for chlamydia
- Ceftriaxone 500 mg IM for gonorrhea
HIV Infection
- Same treatment regimens as HIV-negative patients
- Treatment reduces cervical HIV shedding and lowers transmission risk
Other Management
| Action | Detail |
|---|---|
| Abstinence | Until patient and partner(s) complete treatment AND symptoms resolve (7 days after single-dose or after completing a 7-day course) |
| Partner management | Sex partners should be evaluated and treated with a regimen matched to the woman's diagnosis |
| Syphilis + HIV testing | Offer to all women diagnosed with cervicitis |
| Follow-up | Return visit to confirm resolution; if symptoms persist, re-evaluate |
| Repeat testing | 3 months after treatment for gonorrhea, chlamydia, or trichomoniasis (high reinfection rates) |
Complications If Untreated
- Pelvic inflammatory disease (PID) - 10-40% of untreated gonorrheal cervicitis
- Bartholin gland abscess
- Infertility, ectopic pregnancy (chronic sequelae of PID)
- Obstetric complications in pregnancy (preterm delivery, spontaneous abortion)
Sources:
- Harrison's Principles of Internal Medicine, 22E (2025), Ch. 141 (Mucopurulent Cervicitis section)
- Washington Manual of Medical Therapeutics (Urethritis/Cervicitis table)
- Goldman-Cecil Medicine, Ch. 264 (Cervicitis)
- CDC STI Treatment Guidelines - Urethritis and Cervicitis
This is a shared conversation. Sign in to Orris to start your own chat.